Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Inclusion Criteria: Participant or legally authorized representative has provided signed informed consent (≥18 years of age) and/or assent form (signed by legal representative if participants is <18 years of age). Participant has a documented diagnosis of severe congenital ADAMTS13 deficiency, defined by: Confirmed molecular genetic testing, or ADAMTS13 activity and a negative test for ADAMTS13 antibodies. Participant is currently on a prophylactic regimen or has a documented history of at least 1 TTP event. Standard of Care (SoC) is considered inadequate, or the participant is intolerant to SoC*. SoC are plasma-based therapies, e.g., fresh frozen plasma or S/D treated plasma Exclusion Criteria: Participant is currently eligible to enter into an interventional clinical trial for cTTP. There is a suitable alternative commercially available treatment for the treatment of cTTP. Participant has been diagnosed with any other thrombotic microangiopathies (TMAs) like disorder (microangiopathic hemolytic anemia), including acquired TTP. Participant has a known hypersensitivity/allergies/intolerance or contraindications to TAK-755 or its excipients, such as hamster proteins. Participant has a medical history or presence of a functional ADAMTS13 inhibitor. Participant has a medical history of genetic or acquired immune deficiency that would interfere with the assessment of product immunogenicity, including Participants who are human immunodeficiency virus (HIV)-positive with an absolute cluster of differentiation 4 (CD4) count <200 per millimeter cube (<200/mm^3) or who are receiving chronic immunosuppressive drugs